Heart muscle injury or further reduction after surgery

Perinatal myocardial ischemic re-perfusion injury is a key risk factor for increased postoperative mortality and disability, which has been paid much clinical attentionAlthough many perioperative cardioprotection measures have been studied and applied, they have had little clinical effectDuring the refilling process of myocardial ischemia, locally produced metabolites and inflammatory media can stimulate the sensation of the heart surface into the neurons, and further transmit this harmful stimulation signal through the back root nerve section (DRG) into the chest spinal cord and the upper center, resulting in pain and cardiovascular neuroreflectionthe study found that NGF plays an important role in this myocardial ischemic harmful signaling processBy constructing slow-virus particles that carry NGF small interference RNA, intra-thoracic injection can cause the silence of ngF genes in the spinal cord and DRGThe study found for the first time that gene silencing in the thoracic spinal cord and DRG gene significantly reduced myocardial ischemic re-injection damage, reduced myocardial infarction area and arrhythmia scoreFurther study of downstream signaling mechanisms found that the effect of NGF gene silencing-mediated cardiomyopathy may be related to the suppression of myocardial ischemia injury perception signals that inhibit TRPV1 dependence, and involves neuropeptide release and Akt and ERK signaling pathways that regulate spinal cord levelsThe study suggests that NGF may be an important target for preventing perioperative myocardial ischemic re-perfusion injury, and that the application of small molecule drugs prior to surgery can be targeted to inhibit the spinal cord NGF or TRPV1, or to reduce heart muscle injury after surgery.